Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Lymphocyte Activating Gene 3 (LAG3) Antibody Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The market size for lymphocyte activating gene 3 (lag3) antibodies has seen substantial growth in recent years. This market is set to increase from $0.8 billion in 2025 to $0.91 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.8%. Key drivers for this historical expansion include the limited availability of lag3 antibodies, a reliance on traditional monoclonal antibody therapies, an expanding oncology pipeline, a rise in academic and clinical research efforts, and regulatory approvals for early-stage antibody treatments.
The lymphocyte activating gene 3 (lag3) antibody market size is projected to experience substantial growth in the coming years. It is forecast to reach $1.53 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 13.9%. This expansion during the projection period is primarily driven by factors such as the development of bispecific and tandem scfv antibodies, the broadening scope of combination immunotherapies, increased adoption in the treatment of autoimmune and infectious diseases, heightened investment in clinical trials and research and development, and their integration with personalized and precision medicine strategies. Noteworthy trends anticipated during the forecast period include the growing utilization of LAG3 antibodies in cancer immunotherapy, the formulation of combination therapies alongside other immune checkpoint inhibitors, an intensified focus on applications for autoimmune diseases, the expansion of clinical trials targeting infectious disease treatments, and the advancement of humanized and bispecific antibody platforms.
Get A Free Sample Report With In-Depth Market Insights:
Lymphocyte Activating Gene 3 (LAG3) Antibody Market Demand Drivers Opening New Revenue Streams
The increasing occurrence of cancer is anticipated to fuel the expansion of the lymphocyte activating gene 3 (LAG3) antibody market moving forward. Cancer incidence defines the count of new cancer diagnoses emerging within a particular population during a specified duration. This increase in cancer incidence is attributed to lifestyle-related factors such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, all of which elevate the risk of developing various forms of cancer. Lymphocyte activating gene 3 (LAG3) antibodies play a role in cancer treatment by re-establishing the function of exhausted T cells, thus proving effective in strengthening the immune system’s activity against tumors. They enhance treatment outcomes by stimulating anti-tumor responses, providing renewed optimism for individuals battling advanced cancers. For instance, in January 2024, as reported by the American Cancer Society, a US-based nonprofit cancer advocacy organization, the volume of cancer cases rose to 2,001,140, up from 1,958,310 in 2023, representing a 2.19% growth. Hence, the escalating cancer incidence is acting as a significant driver for the growth of the lymphocyte activating gene 3 (LAG3) antibody market.
Lymphocyte Activating Gene 3 (LAG3) Antibody Market Segment Performance And Emerging Opportunities
The lymphocyte activating gene 3 (lag3) antibody market covered in this report is segmented –
1) By Type Of Antibodies: Monoclonal Antibody, Polyclonal Antibody, Bispecific Antibodies
2) By Drug Class: Monotherapy, Combination Therapy
3) By Mechanism Of Action: Immune Checkpoint Inhibitors, Immunomodulatory Antibodies, Co-Stimulatory Antibodies
4) By Application: Cancer Immunotherapy, Autoimmune Diseases, Infectious Diseases
5) By End-User: Pharmaceutical And Biotechnology Companies, Academic Research Institutions, Diagnostic Laboratories
Subsegments:
1) By Monoclonal Antibody: Human Monoclonal Antibody, Humanized Monoclonal Antibody, Chimeric Monoclonal Antibody
2) By Polyclonal Antibody: Rabbit Polyclonal Antibody, Goat Polyclonal Antibody, Mouse Polyclonal Antibody, Donkey Polyclonal Antibody
3) By Bispecific Antibodies: Tandem ScFv Based Bispecific Antibody, Dual Variable Domain Based Bispecific Antibody, Bispecific T Cell Engager, Immunoglobulin G such as Bispecific Antibody
Lymphocyte Activating Gene 3 (LAG3) Antibody Market Trends Powering Strategic Industry Growth
Leading firms within the Lymphocyte Activating Gene 3 (LAG3) Antibody market are prioritizing clinical trials aimed at creating novel products like advanced monoclonal antibodies, intending to boost anti-tumor immune responses and address resistance encountered with current immunotherapies. These advanced, engineered antibody therapies, known as next-generation monoclonal antibodies, are crafted to bind immune targets, including LAG-3, with enhanced precision, greater specificity, increased stability, and stronger functional potency. Their purpose is to improve T-cell activation, bolster anti-tumor responses, and overcome shortcomings of previous antibody treatments. As an example, in February 2025, the US-based biopharmaceutical entity Bristol-Myers Squibb Company issued an update concerning its fixed-dose combination product, Opdualag (nivolumab + relatlimab-rmbw). This product represents a pioneering dual immunotherapy, comprising the LAG-3-blocking antibody relatlimab alongside the PD-1 inhibitor nivolumab. Opdualag combines a humanized IgG4 monoclonal LAG-3 antibody (relatlimab) with a PD-1 inhibitor (nivolumab), administered intravenously every 4 weeks. Its mechanism of action involves inhibiting both the LAG-3–ligand interaction, which prevents T-cell exhaustion, and PD-1–ligand binding. This dual blockade stimulates T-cell proliferation and cytokine secretion more effectively than PD-1 monotherapy alone. Noteworthy attributes include its fixed-dose combination (480 mg nivolumab + 160 mg relatlimab) and its distinction as the initial approved therapy to target LAG-3 in a combined approach. Its indications span adult and pediatric patients (aged 12 years and older) suffering from unresectable or metastatic melanoma, providing an advantage over conventional PD-1 inhibitor monotherapy regarding progression-free survival.
Lymphocyte Activating Gene 3 (LAG3) Antibody Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the lymphocyte activating gene 3 (lag3) antibody market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Ono Pharmaceutical Co. Ltd., Xencor Inc., Innovent Biologics Inc., Zai Lab Limited, MacroGenics Inc., Akeso Inc., Agenus Inc., Alphamab Oncology, AnaptysBio Inc., Crescendo Biologics Ltd., EpimAb Biotherapeutics Inc., Shanghai Henlius Biotech Inc., Immutep Limited
View The Full Lymphocyte Activating Gene 3 (LAG3) Antibody Market Report:
Lymphocyte Activating Gene 3 (LAG3) Antibody Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the lymphocyte activating gene 3 (LAG3) antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lymphocyte activating gene 3 (lag3) antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model